MedTrace Logo

A Retrospective Comparison of the Efficacy and Safety of Celsior® in Pediatric Cardiac Surgery for Transposition of the Great Vessels

NCT04616222 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2020-11-06

No results posted yet for this study

Summary

Celsior® is an organ preservation solution used for the harvesting and the preservation of solid organs. Its use as a crystalloid cardioplegia solution has been established recently. Its main advantage is the long duration of myocardial protection. Compared to the other cardioplegia solutions, it allows a reduced amount of solution administered during the surgery and fewer interruptions during the intervention for the administration of supplemental doses of cardioplegia for long and complex operations.

The objective of this register is to compare the safety and the efficacy of Celsior® to the old cardioplegia solution Saint-Thomas used as cardioplegia solution in surgery of the transposition of great vessels, the arterial switch operation.

Conditions

  • Transposition of Great Vessels

Interventions

DRUG

CELSIOR® group

Patient who received Celsior® during their transposition of the great vessels surgery according to the routine care.

DRUG

Saint-Thomas group

Patient who received Saint-Thomas during their transposition of the great vessels surgery according to the routine care.

Sponsors & Collaborators

  • Hospices Civils de Lyon

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2020-12-01
Completion
2020-12-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04616222 on ClinicalTrials.gov